
ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
Welcome back to Kidney Compass!
Recording from ASN Kidney Week 2026 in Denver, Colorado, cohosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, sat down with Jonathan Barratt, PhD, FRCP, of the University of Leicester, shortly after he presented the final efficacy analysis of the phase 3 ORIGIN 3 trial at the opening plenary.
The results, published simultaneously in the New England Journal of Medicine, show atacicept, a dual B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, stabilized eGFR over 1 year.¹,² The conversation moved from the data to trial design, treatment sequencing, and global access.
Key Episode Timestamps
00:00 - IgA nephropathy takes over the ASN plenary
01:33 - ORIGIN 3 final analysis: eGFR, proteinuria, and kidney outcomes
05:18 - Why the eGFR end point moved to week 52
06:44 - Consistency across prespecified subgroups
08:38 - Placebo-group discontinuations and future trial design
10:32 - Should B-cell therapy come first in IgA nephropathy?
13:57 - Choosing among APRIL and BAFF/APRIL inhibitors
15:37 - Global access to new IgA nephropathy therapies
Altri episodi di "Kidney Compass: Navigating Clinical Trials"



Non perdere nemmeno un episodio di “Kidney Compass: Navigating Clinical Trials”. Iscriviti all'app gratuita GetPodcast.








